Glyn Tamara, Purcell Rachel
Department of Surgery, University of Otago, Christchurch, New Zealand.
Front Med (Lausanne). 2022 Apr 4;9:831096. doi: 10.3389/fmed.2022.831096. eCollection 2022.
Cell-free DNA applications for screening, diagnosis and treatment monitoring are increasingly being developed for a range of different cancers. While most of these applications investigate circulating tumor DNA (ctDNA) or methylation profiles of ctDNA, circulating bacterial DNA (cbDNA) has also been detected in plasma and serum samples from cancer patients. Recent publications have the detection of cbDNA in studies of breast, gastric, colorectal, hepatocellular and ovarian cancers. In several cases, distinction between patients and healthy controls was possible, based on cbDNA profiles, in addition to potential prognostic value. A large pan-cancer study demonstrated the feasibility of cbDNA to distinguish between four types of cancer and healthy controls, even in patients with early-stage disease. While improvements in, and standardization of laboratory and bioinformatics analyses are needed, and the clinical relevance of cbDNA yet to be ascertained for each cancer type, cbDNA analysis presents an exciting prospect for future liquid biopsy screening and diagnostics in cancer.
无细胞DNA在一系列不同癌症的筛查、诊断和治疗监测中的应用正在不断发展。虽然这些应用大多研究循环肿瘤DNA（ctDNA）或ctDNA的甲基化谱，但在癌症患者的血浆和血清样本中也检测到了循环细菌DNA（cbDNA）。最近的出版物报道了在乳腺癌、胃癌、结直肠癌、肝细胞癌和卵巢癌研究中检测到cbDNA。在一些情况下，除了潜在的预后价值外，基于cbDNA谱还能够区分患者和健康对照。一项大型泛癌研究证明了cbDNA区分四种癌症类型和健康对照的可行性，即使在早期疾病患者中也是如此。虽然实验室和生物信息学分析需要改进和标准化，并且每种癌症类型的cbDNA的临床相关性尚待确定，但cbDNA分析为未来癌症液体活检筛查和诊断提供了令人兴奋的前景。
